prikaz prve stranice dokumenta Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
Prostaglandins, Leukotrienes and Essential Fatty Acids, 204 (2025); 102665. https://doi.org/10.1016/j.plefa.2025.102665
Nadalin, Sergej; Ljoka, Ivan; Savić, Aleksandar; Silić, Ante; Peitl, Vjekoslav; Karlović, Dalibor; Vilibić, Maja; Zatković, Lena; Buretić-Tomljanović, Alena

Citations:
,
Cite this document

Nadalin, S., Ljoka, I., Savić, A., Silić, A., Peitl, V., Karlović, D. ... Buretić Tomljanović, A. (2025). Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids, 204.. doi: 10.1016/j.plefa.2025.102665

Nadalin, Sergej, et al. "Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients." Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 204, 2025. https://doi.org/10.1016/j.plefa.2025.102665

Nadalin, Sergej, Ivan Ljoka, Aleksandar Savić, Ante Silić, Vjekoslav Peitl, Dalibor Karlović, Maja Vilibić, Lena Zatković and Alena Buretić Tomljanović. "Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients." Prostaglandins, Leukotrienes and Essential Fatty Acids 204 (2025). https://doi.org/10.1016/j.plefa.2025.102665

Nadalin, S., et al. (2025) 'Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients', Prostaglandins, Leukotrienes and Essential Fatty Acids, 204. doi: 10.1016/j.plefa.2025.102665

Nadalin S, Ljoka I, Savić A, Silić A, Peitl V, Karlović D, and sur.. Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids [Internet]. 2025 April [cited 2025 March 17];204. doi: 10.1016/j.plefa.2025.102665

S. Nadalin, et al., "Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients", Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 204, April 2025. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:570176. [Accessed: 17 March 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
AuthorSergej Nadalin
AuthorIvan Ljoka
AuthorAleksandar Savić
AuthorAnte Silić
AuthorVjekoslav Peitl
AuthorDalibor Karlović
AuthorMaja Vilibić
AuthorLena Zatković
AuthorAlena Buretić-Tomljanović
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Biology and Medical Genetics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Psychiatry
Abstract (english)
Several studies have shown antipsychotic effects of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib as an add-on treatment to antipsychotic treatment. The functional rs689466 (A/G) polymorphism in the gene encoding COX-2 (also known as the prostaglandin-endoperoxide synthase 2 gene) has been correlated with schizophrenia risk and the niacin skin flush response among chronic patients under antipsychotic treatment. Here, we investigated whether this polymorphism was associated with... More antipsychotic treatment in a group of total psychosis patients (N = 186), as well as a subgroup of patients treated with clozapine (N = 74). Antipsychotic-naïve first-episode patients and non-adherent chronic psychosis patients were genotyped by polymerase chain reaction/restriction fragment length polymorphism analysis. At baseline and after 8 weeks of treatment with various antipsychotic medications, we assessed the patients’ Positive and Negative Syndrome Scale (PANSS) scores, factors, and metabolic syndrome-related parameters, including fasting plasma lipid and glucose levels and body mass index. In the total patient group, the COX-2 polymorphism was not associated with PANSS psychopathology scores or metabolic parameters. However, in the subgroup of patients treated with clozapine, the COX-2 polymorphism was associated with changes in plasma HDL cholesterol. Specifically, compared to patients homozygous for the A allele, the subgroup of patients treated with clozapine and positive for the G allele (i.e., GG or AG genotype) exhibited significantly higher increases in HDL cholesterol levels. The COX-2 polymorphism had a moderate effect size but made a relatively weak contribution to variations in the HDL cholesterol level (∼9.6 %). Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleProstaglandins, Leukotrienes and Essential Fatty Acids
Numberingvol. 204, 102665
p-ISSN0952-3278
DOIhttps://doi.org/10.1016/j.plefa.2025.102665
URN:NBNurn:nbn:hr:184:570176
Publication2025-04
ProjectNumber: uniri-biomed-18-251
Title (croatian): Genetički i biokemijski biljezi metabolizma membranskih fosfolipida i masnih kiselina kao predskazatelji odgovora na antipsihotičnu terapiju u bolesnika s psihotičnom epizodom
Title (english): Genetic and biochemical markers of the membrane phospholipid and fatty acid metabolism as predictors of treatment response to antipsychotic therapy in patients with psychotic episodes
Leader: Alena Buretić-Tomljanović
Jurisdiction: Croatia
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S095232782500002X
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2025-03-11 08:28:19
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.